Clostridium difficile antibody and antigen (recombinant protein)

Diagnostic anti-Clostridium difficile antibodies pairs and antigen for animal health (animal Cat/Feline, Dog/Canine, Equine/Horse, Swine/Porcine/Pig infectious disease Clostridiosis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Multiple species disease testing products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-VT-P263-Ag01 Recombinant Clostridium difficile protein $3090.00
GMP-VT-P263-Ab01 Anti-Clostridium difficile mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P263-Ab02 Anti-Clostridium difficile mouse monoclonal antibody (mAb) $3090.00

Size: 1mg | 10mg | 100mg



Product Description

Cat No. GMP-VT-P263-Ag01
Product Name Recombinant Clostridium difficile protein
Pathogen Clostridium difficile
Expression platform E.coli
Isotypes Recombinant Antigen
Bioactivity validation Anti-Clostridium difficile antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Clostridium difficile level test of animal Cat/Feline, Dog/Canine, Equine/Horse, Swine/Porcine/Pig infectious disease with Clostridiosis.
Tag His
Product description Recombinant Clostridium difficile proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P263-Ab01,GMP-VT-P263-Ab02
Pathogen Clostridium difficile
Product Name Anti-Clostridium difficile mouse monoclonal antibody (mAb)
Expression platform CHO
Isotypes Mouse IgG
Bioactivity validation Recombinant Clostridium difficile antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Clostridium difficile antibodies in Clostridium difficile level test of animal Cat/Feline, Dog/Canine, Equine/Horse, Swine/Porcine/Pig infectious disease with Clostridiosis.
Product description Anti-Clostridium difficile mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Clostridium difficile antibodies./td>
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Pathogen


    Clostridium difficile is a Gram-positive, anaerobic, spore-forming bacterium commonly found in the environment, such as soil, human and animal feces. It is known to be a primary cause of antibiotic-associated diarrhea (AAD), which often occurs when antibiotics disrupt the natural balance of bacteria in the gut.

    The pathogen has been classified into five different types (PCR ribotypes), with type 027 being associated with more severe infections and higher mortality rates. Its genome contains more than 4000 genes, and more than ten per-cent of them encode bacterial toxins, adherence factors, and other virulence factors that contribute to its pathogenicity. These virulence factors include the tcdA and tcdB genes, which encode two large toxins, TcdA and TcdB, responsible for the colon's epithelial cell death and tissue damage. TcdA and TcdB also stimulate proinflammatory cytokine release, leading to intestinal inflammation and neutrophil infiltration. The flagellin protein is another virulence factor produced by C. difficile, which is involved in bacterial movement, colonization, and evasion of the host's immune system.

    Clostridium difficile primarily infects individuals who have recently taken antibiotics or are immunocompromised. It can cause several diseases, including AAD, pseudomembranous colitis, and toxic megacolon. AAD is the most common manifestation of C. difficile infection (CDI) and occurs when the antibiotics kill off beneficial bacteria in the colon, allowing C. difficile to proliferate rapidly. Pseudomembranous colitis occurs when the bacteria damage the colon's epithelial cell lining, leading to inflammation and the formation of yellowish plaques of inflammatory debris and mucus. Toxic megacolon occurs when the colon's inflammation and dilation cause it to lose its muscular tone, leading to bowel perforation.

    Several diagnostic methods are available for detecting C. difficile infections, including stool tests, toxin assays, PCR, and enzyme immunoassays. These tests detect the presence of C. difficile toxins or genetic material within a patient's fecal sample. The most commonly used diagnostic method is a stool test that detects C. difficile antigen, which indicates active infection. Toxin assays, such as the ImmunoCard Toxins A&B assay, detect the presence of TcdA and TcdB toxins in a patient's fecal sample. PCR is another diagnostic method that amplifies specific genetic sequences unique to C. difficile, such as the tcdA and tcdB genes. Enzyme immunoassays, such as the AmpliVue C. difficile assay, utilize probes that target both tcdA and tcdB simultaneously, resulting in a more sensitive and specific test.

    In addition to standard laboratory tests, researchers have developed several novel approaches to detect C. difficile infections, such as mass spectrometry, antigen detection assays, and next-generation sequencing. Mass spectrometry can identify small molecule biomarkers unique to C. difficile infection, while antigen detection assays target specific viral or bacterial antigens as biomarkers. Next-generation sequencing allows for the rapid detection of C. difficile by sequencing bacterial DNA directly from a patient's fecal sample.

    In conclusion, Clostridium difficile is a significant human pathogen that causes a range of intestinal infections, primarily among individuals who have recently taken antibiotics. Its virulence factors, such as TcdA, TcdB, and flagellin, contribute to its pathogenicity by disrupting the epithelial cell lining of the colon and evading the host's immune system. Several diagnostic methods are available to detect C. difficile infections, including traditional laboratory tests, as well as novel approaches. Early and accurate diagnosis is critical for successful treatment and to prevent the spread of this pathogen in healthcare settings.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.